Safety of peginterferon in the treatment of chronic hepatitis C

Expert Opinion on Drug Safety

Volumn 7, Issue 6, 2008, Pages 771-781

  Hashemi, Nikroo ^a   Rossi, Simona ^a   Navarro, Victor J ^a   Herrine, Steven K ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Adverse events; Chronic hepatitis C; pegIFN 2a; pegIFN 2b; Safety; Side effects

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; BETA 2 MICROGLOBULIN; CELL SURFACE RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEIN TYROSINE KINASE; RIBAVIRIN;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CARDIOMYOPATHY; CELL PROLIFERATION; CLINICAL TRIAL; COLON ISCHEMIA; COLOR VISION DEFECT; CONCENTRATION LOSS; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSPEPSIA; DYSPNEA; ENZYME ACTIVATION; ENZYME SYNTHESIS; FATIGUE; FEVER; GRAVES DISEASE; HEADACHE; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IMMUNOMODULATION; INFORMATION RETRIEVAL; INHIBITION KINETICS; INJECTION SITE INFLAMMATION; INJECTION SITE REACTION; INSOMNIA; IRRITABILITY; ISCHEMIC COLITIS; LUPUS ERYTHEMATOSUS; MEDICAL LITERATURE; MENTAL HEALTH; MENTAL INSTABILITY; MUSCLE HYPERTONIA; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEUTROPENIA; OPTIC NEURITIS; PAPILLEDEMA; PATIENT COMPLIANCE; PERIODONTAL DISEASE; PRURITUS; PSORIASIS; RASH; RECEPTOR BINDING; RECOMMENDED DRUG DOSE; RETINA ARTERY OCCLUSION; RETINA HEMORRHAGE; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; RIGOR; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TOOTH DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; ULCERATIVE COLITIS; VIRUS REPLICATION; VOMITING; WEIGHT REDUCTION;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MEDICATION ADHERENCE; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 57049161561     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330802423291     Document Type: Article

References (102)

1. Davis FF, Abuchowski A, Van Es T. Enzyme-polyethylene glycol adducts: modified enzymes with unique properties. Enzyme Eng 1978;4:169-73
2. He XH, Shaw PC, Tam SC. Reducing the immunogenicity and improving the in vivo activity of tricosanthin by site-directed pegylation. Life Sci 1999;65:355-68
3. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa 2-b plus ribavirin compared with interferon alfa 2-b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958-65
4. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82
5. Wills RJ. Clinical Pharmacology of interferons. Clin Pharmacokinet 1990;19:390-9
6. Gale M Jr. Effector genes of interferon action against hepatitis C virus. Hepatology 2003;37:975-8
7. Sen GC. Viruses and interferons. Ann Rev Microbiol 2001;55:255-81
8. Meyer Wyss B, Rich P, Egger H, et al. Comparison of two PEG-interferon alfa-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis. J Viral Hepat 2006;13:457-65
9. Tilg H. New insights into the mechanisms of interferon: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 1997;112:1017-21
10. Haria M, Benfield P. Interferon-alfa-2a: a review of its pharmacological properties and therapeutic use in the management of viral hepatitis. Drugs 1995;50:873-96
11. Smith RA, Norris F, Palmer D, et al. Distribution of alfa interferon in serum and cerebrospinal fluid after systemic administration. Clin Pharmacol Ther 1985;37:85-8
12. Peg-Intron® (peginterferon alfa-2b) package insert. Kelinworth, NJ: Schering Corporation; 2005. Available from: http://www.spfiles.com/ pipeg-intron.pdf [Last accessed June 2008]
13. Pegasys® (peginterferon alfa-2a) package insert. Nutley, NJ: Hoffmann-La Roche Inc.; 2002. Available from: http://pegasys.com/hcp/ default.aspx [Last accessed June 2008]
14. Harrison's Online. Part 13: Disorders of the Gastrointestinal System. Section 2: Liver and Biliary Tract Disease, Chapter 300. Chronic Hepatitis. Available from: http://www.accessmedicine.com/ content.aspx?aID=2876243&searchStr=peginterferon [Last accessed July 2008]
15. Jacobson IM, Brown RS Jr, Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007;46:971-81
16. Di Marco V, Almasio PL, Ferraro D, et al. Peginterferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol 2007;47:484-91
17. Abergel A. Hezode C, Leroy V, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alfa-2b. J Viral Hepat 2006;13:811-20
18. Linsday K, Trepo C, Heintegs T, et al. A randomized, double-blind trial comparing pegylated interferon alfa 2-b to interferon alfa 2-b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403
19. Hasan F, Asker H, Al-Khaldi J, et al. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 2004;99:1733-7
20. Glue P, Fang J, Rouzier-Panis R, et al. Pegylated interferon-α2b: pharmacokinetics, pharmacodynamics, safety and preliminary efficacy data. Clin Pharmacol Ther 2000;68:556-67
21. Milkiewicz P, Yim C, Pache I, et al. Diffuse skin reaction in patient with hepatitis B, treated with two different formulations of pegylated interferon. Can J Gastroenterol 2005;19:677-8
22. Manjón-Haces JA, Vázquez-López F, Gómez-Díez S, et al. Adverse cutaneous reactions to interferon alfa-2b plus ribavirin therapy in patients with chronic hepatitis C virus. Acta Derm Venereol 2001;8:223
23. Hashimoto Y, Kanto H, Rob M. Adverse skin reactions due to pegylated interferon alfa 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus. J Dermatol 2007;34:577-82
24. Kartal ED, Colak H, Ozgunes I, Usluer G. Exacerbation of psoriasis due to peginterferon alfa-2b plus ribavirin treatment of chronic active hepatitis C. Chemotherapy 2005;51:167-9
25. Dereure O, Raison-Peyron N, Larrey D, et al. Diffuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C. A series of 20 patients. Br J Dermatol 2002;147:1142-6
26. Kartal ED, Alpat SN, Ozgunes I, et al. Reversible alopecia universalis secondary to PEG-intefferon alfa-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Eur J Gastroenterol Hepatol 2007;19:817-2
27. Taliani G, Biliotti E, Capanni M, et al. Reversible alopecia universalis during treatment with PEG-interferon and ribavirin for chronic hepatitis C. Chemotherapy 2005;17:212-4
28. Demirturk N, Aykin N, Demirdal T, et al. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin. Eur J Dermatol 2006;16:579-80
29. Stryjek-Kaminska D, Ochsendorf F, Roder C, et al. Photoallergic skin reaction to ribavirin. Am J Gastroenterol 1999;94:1686-8
30. Sookoian S, Neglia V, Castano G, et al. High prevalence of cutaneous reactions to interferon alfa plus ribavirin combination therapy in patients with chronic hepatitis C virus. Arch Dermatol 1999;135:1000-1
31. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36:S237-44
32. Balan V, Schwartz D, Wu GY, et al. Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ ribavirin. Am J Gastroenterol 2005;100:299-307
33. Kowdley KV. Hematologic side effects of interferon and ribavirin therapy [review]. J Clin Gastroenterol 2005;39(Suppl 1):S3-8
34. Koirala J, Gandotra SD, Rao S, et al. Granulocyte colony-stimulating factor dosing in pegylated interferon alfa-induced neatropenia and its impact on outcome of anti-HCV therapy. J Viral Hepat 2007;14:782-7
35. Dar Santos AE, Partovi N, Ford JA, et al. Use of hematopoietic growth factors as adjuvant therapy for anemia and neutropenia in the treatment of hepatitis C. Ann Pharmacother 2007;41:268-75
36. Koliouskas D, Didiropoulos I, Masmanidou M, et al. Comparative analysis and effect of GM-CSF on neutropenia in peg-interferon alfa-2b and ribavirin-treated chronic hepatitis C patients [abstract]. Hepatology 2002;36:587A
37. Rifflet H, Vuillemin E, Oberti F, et al. Suicidal impulses in patients with chronic viral hepatitis C during or after therapy with interferon alfa. Gastroenterol Clin Biol 1998;22:353-7
38. Raison CL, Borisov AS, Broadwell SD, et al. Depression during pegylated interferon-alfa plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 2005;66:41-8
39. Schaefer M, Engelbrecht MA, Gut O, et al. Interferon alfa (IFN alfa) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:731-46
40. Loftis JM, Hauser P. The phenomenology and treatment of interferon-induced depression. J Affect Disord 2004;82(2):175-90
41. Bonaccorso S, Marino V, Biondi M, et al. Depression induced by treatment with interferon-alfa in patients affected by hepatitis C virus. J Affect Disord 2002;72(3):237-41
42. Janssen HL, Brouwer JT, Van Der Mast RC, et al. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994;21:241-3
43. Kraus MR, Schäfer A, Schöttker K, et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut 2008;57:531-6
44. Kraus MR, Schäfer A, Csef H. Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C. World J Gastroenterol 2005;11:1769-74
45. Kraus MR, Schäfer A, Faller H, et al. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 2003;64:708-14
46. Bagheri H, Fouladi K, Barange A, et al. Follow-up of adverse drug reactions from peginterferon alfa-2b-ribavirin therapy. Pharmacotherapy 2004;24:1546-53
47. Constant A, Castera L, Dantzer R, et al. Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry 2005;66:1050-7
48. Kalyoncu OA, Tan D, Mirsal H, et al. Major depressive disorder with psychotic features induced by interferon-alfa treatment for hepatitis C in a polydrug abuser. J Psychopharmacol 2005;19:102-5
49. Schafer M, Boetsch T, Laakmann G. Psychosis in a methadone-substituted patient during interferon-alfa treatment of hepatitis C. Addiction 2000;95:1101-4
50. Basanth KK, Jacob R, Jacob KS. Mania associated with interferon alfa2b treatment. J Postgrad Med 2006;52:207-9
51. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003;37(2):443-51
52. Schaefer M, Hinzpeter A, Mohmand A, et al. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alfa and ribavirin: response and psychiatric side effects. Hepatology 2007;46(4):991-8
53. Geppert CM, Arora S. Widening the door: the evolution of hepatitis C treatment in patients with psychiatric disorders. Hepatology 2007;46:957-9
54. Knott A, Dieperink E, Willenbring ML, et al. Integrated psychiatric/ medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol 2006;101:2254-62
55. Schaefer M, Schwaiger M, Garkisch AS, et al. Prevention of interferon-alfa associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005;42:793-8
56. Morasco BJ, Rifai MA, Loftis JM, et al. A randomized trial of paroxetine to prevent interferon-affa-induced depression in patients with hepatitis C. J Affect Disord 2007;103:83-90
57. Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002;7:942-7
58. Bacon BR. Managing hepatitis C [review]. Am J Manag Care 2004;10(Suppl 2):S30-40
59. Leung Y, Urbanski SJ, Schindel L, et al. Ischemic colitis during pegylated interferon-alfa and ribavirin therapy for chronic hepatitis C. Can J Gastroenterol 2006;20:661-3
60. Punnam SR, Pothula VR, Gourineni N, et al. Interferon-ribavirin-associated ischemic colitis. J Clin Gastroenterol 2008;42:323-5
61. Tada H, Saitoh S, Nakagawa Y, et al. Ischemic colitis during interferon-alfa treatment for chronic active hepatitis C. J Gastroenterol 1996;31:582-4
62. Tursi A. Rapid onset of ulcerative colitis after treatment with PEG-interferon plus ribavirin for chronic hepatitis C. Inflamm Bowel Dis 2007;13:1189-90
63. Watanabe T, Inoue M, Harada K, et al. A case of exacerbation of ulcerative colitis induced by combination therapy with PFG-interferon alfa-2b and ribavirin. Gut 2006;55:1682-3
64. Cecchi E, Forte P, Cini E, et al. Pancreatitis induced by pegylated interferon alfa-2b in a patient affected by chronic hepatitis C. Emerg Med Australas 2004;16:473-5
65. Ozdogan O, Tahan V, Cincin A, et al. Acute pancreatitis associated with the use of peginterferon. Pancreas 2007;34:485-7
66. Thurairajah PH, Thorburn D, Hubscher S, et al. Incidence and characterization of serum transaminases elevations in pegylated interferon and ribavirin treated patients with chronic hepatitis C. Aliment Pharmacol Ther 2007;25:1293-300
67. Kuwata A, Ohashi M, Sugiyama M, et al. A case of reversible dilated cardiomyopathy after alfa-interfefon therapy in a patient with renal cell carcinoma. Am J Med 2002;324:331-4
68. Kruit WH, Punt KJ, Goey SH, et al. Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alfa-interferon. An unexpectedly frequent complication. Cancer 1994;74:2850-6
69. Teragawa H, Hondo T, Amano H, et al. Adverse effects of interferon on the cardiovascular system in patients with chronic hepatitis C. Jpn Heart J 1996;37:905-15
70. Condat B, Asselah T, Zanditenas D, et al. Fatal cardiomyopathy associated with pegylated interferon/ribavirin in a patient with chronic hepatitis C. Eur J Gastroenterol Hepatol 2006;18:287-9
71. Kumar KS, Russo MW, Borczuk AC, et al. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol 2002;97:2432-40
72. Renou C, Germain S, Harafa A, et al. Interstitial pneumonia recurrence during chronic hepatitis C treatment. Am J Gastroenterol 2005;100:1625-6
73. Chen YC, Lu SN, Lin MC. Interstitial pneumonitis after combination therapy with pegylated interferon alfa-2b and ribavirin for chronic hepatitis C. Chang Gung Med J 2007;30:92-7
74. Doyle MK, Berggren R, Magnus JH. Interferon-induced sarcoidosis. J Clin Rheumatol 2006;12:241-8
75. Prummel MF, Laurberg P. Interferon-alfa and autoinumme thyroid disease. Thyroid 2003;13:547-51
76. Hsieh MC, Yu ML, Chuang WL, et al. Virologic factors related to interferon-alfa-induced thyroid dysfunction in patients with chronic hepatitis C. Eur J Endocrinol 2000;142:431-7
77. Watanabe U, Hashimoto E, Hisamitsu T, et al. The risk factor for development of thyroid disease during interferon-alfa therapy for chronic hepatitis C. Am J Gastroenterol 1994;89:399-403
78. Deutsch M, Dourakis S, Manesis EK, et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 1997;26:206-10
79. Dalgard O, Bjoro K, Hellum K, et al. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alfa: no association with either interferon dosage or efficacy of therapy. J Intern Med 2002;251:400-6
80. Pellicano R, Smedile A, Peyre S, et al. Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: the hepatologist's view. Minerva Gastroenterol Dietol 2005;51:55-61
81. Kee KM, Lee CM, Wang JH, et al. Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis. J Gastroenterol Hepatol 2006;21:319-26
82. Bini EJ, Mehandru S. Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study. Arch Intern Med 2004;164:2371-6
83. Eibl N, Gschwantler M, Ferenci P, et al. Development of insulin-dependent diabetes mellitus in a patient with chronic hepatitis C during therapy with interferon-alfa. Eur J Gastroentefol Hepatol 2001;13:295-8
84. Cozzolongo R, Betterle C, Fabris P, et al. Onset of type 1 diabetes mellitus during peginterferon alfa-2b plus ribavirin treatment for chronic hepatitis C. Eur J Gastroenterol Hepatol 2006;18:689-92
85. Schreuder TC, Gelderblom HC, Weegink CJ, et al. High incidence of type 1 diabetes mellitus during of shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection. Liver Int 2008;28:39-46
86. Fabris P, Floreani A, Tositti G, et al. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 2003;18:549-58
87. Kawano T, Shigehira M, Uto H, et al. Retinal complications during interferon therapy for chronic hepatitis C. Am J Gastroenterol 1996;91:309-13
88. Manesis EK, Moschos M, Brouzas D, et al. Neurovisual impairment: a frequent complication of alfa-interferon treatment in chronic viral hepatitis. Hepatology 1998;27:1421-7
89. Manesis EK, Petrou C, Brouzas D, et al. Optic tract neuropathy complicating low-dose interferon treatment. J Hepatol 1994;21:474-7
90. Andrade RJ, González FJ, Vázquez L, et al. Vascular ophthalmological side effects associated with antiviral therapy for chronic hepatitis C are related to vascular endothelial growth factor levels. Antivir Ther 2006;11(4):491-8
91. Neubauer AS, Hoops JP. Interferon-induced retinopathy in asymptomatic cancer patients. Ophthalmology 2002;109:821-2
92. Guyer DR, Tiedman J, Yannuzzi La, et al. Interferon-associated retinopathy. Arch Ophthalmol 1993;111:350-60
93. Yan KK, Dinihan I, Freiman J, et al. Sarcoidosis presenting with granulomatous uveitis induced by pegylated interferon and ribavirin therapy for Hepatitis C. Intern Med J 2008;38(3):207-10
94. Lodato F, Tame MR, Colecchia A, et al. Systemic lupus erythematosus following virological response to peginterferon alfa-2b in a transplanted patient with chronic hepatitis C recurrence. World J Gastroenterol 2006;12:4253-5
95. Deutsch M, Manesis EK, Hadziyannis E, et al. Thrombotic thrombocytopenic purpura with fatal outcome in a patient with chronic hepatitis C treated with pegylated interferon-a/2b. Scand J Gastroenterol 2007;42:408-9
96. Siciliano R, Trovato BA, Seminara G, et al. Interferon or hepatitis C virus induced autoimmune aplastic anemia and severe thrombocytopenia? A case report. Ann Ital Med Int 1995;10:193-4
97. Sulkowski M, Lawitz E. Shiffman ML, et al. Final results of the IDEAL (Individualized Dosing Efficacy versus flat dosing to Assess optimal pegylated interferon therapy) Phase IIIB study. J Hepatology 2008;48:S991
98. Von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129:522-7
99. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-17
100. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357:124-34
101. Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008;47:1884-93
102. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002 June 10-12. HIV Clin Trials 2003;4:55